IRIS
GIAMPIERI, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.878
EU - Europa 3.742
AS - Asia 3.728
SA - Sud America 924
Continente sconosciuto - Info sul continente non disponibili 292
AF - Africa 263
OC - Oceania 4
Totale 18.831
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.605
SG - Singapore 1.236
IT - Italia 767
BR - Brasile 738
VN - Vietnam 722
CN - Cina 687
RU - Federazione Russa 625
UA - Ucraina 436
DE - Germania 329
SE - Svezia 325
HK - Hong Kong 319
IE - Irlanda 310
FR - Francia 219
TR - Turchia 218
FI - Finlandia 195
GB - Regno Unito 169
DK - Danimarca 152
CA - Canada 126
IN - India 115
CI - Costa d'Avorio 99
BD - Bangladesh 87
KR - Corea 84
AR - Argentina 70
MA - Marocco 57
MX - Messico 54
ZA - Sudafrica 49
NL - Olanda 48
JP - Giappone 47
PL - Polonia 38
IQ - Iraq 37
ES - Italia 33
CO - Colombia 31
EC - Ecuador 28
ID - Indonesia 27
VE - Venezuela 20
MY - Malesia 19
BE - Belgio 18
IL - Israele 18
HN - Honduras 16
CR - Costa Rica 15
GT - Guatemala 15
PK - Pakistan 14
UZ - Uzbekistan 14
CL - Cile 13
AT - Austria 12
AZ - Azerbaigian 12
TH - Thailandia 11
TN - Tunisia 11
DZ - Algeria 10
SK - Slovacchia (Repubblica Slovacca) 10
LT - Lituania 9
SA - Arabia Saudita 9
CZ - Repubblica Ceca 8
KE - Kenya 8
PH - Filippine 8
PR - Porto Rico 8
PY - Paraguay 8
TT - Trinidad e Tobago 8
EG - Egitto 7
PE - Perù 7
RS - Serbia 7
SV - El Salvador 7
TW - Taiwan 7
AE - Emirati Arabi Uniti 6
JM - Giamaica 6
NI - Nicaragua 6
SC - Seychelles 6
UY - Uruguay 6
ET - Etiopia 5
EU - Europa 5
PA - Panama 5
PT - Portogallo 5
RO - Romania 5
AU - Australia 4
BH - Bahrain 4
CW - ???statistics.table.value.countryCode.CW??? 4
JO - Giordania 4
KG - Kirghizistan 4
KZ - Kazakistan 4
AL - Albania 3
AM - Armenia 3
AO - Angola 3
BO - Bolivia 3
GP - Guadalupe 3
HR - Croazia 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
GR - Grecia 2
LB - Libano 2
LY - Libia 2
MD - Moldavia 2
MK - Macedonia 2
NG - Nigeria 2
NP - Nepal 2
BB - Barbados 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
Totale 18.533
Salva come PNG Salva come JPEG
Città #
Ashburn 1.864
Singapore 803
Chandler 624
San Jose 499
Fairfield 497
Jacksonville 470
Des Moines 352
Council Bluffs 346
Dallas 338
Hong Kong 306
Dublin 305
Boardman 292
New York 275
Wilmington 262
Ho Chi Minh City 230
Woodbridge 227
Seattle 198
Beijing 196
Houston 190
Hanoi 181
Los Angeles 167
The Dalles 164
Ann Arbor 160
Cambridge 148
Princeton 133
Lauterbourg 113
Lawrence 113
Centro 105
Moscow 104
San Mateo 104
Abidjan 98
Munich 90
Santa Clara 77
Turin 71
Turku 70
Milan 65
Buffalo 62
São Paulo 61
Chicago 58
Hefei 54
Orem 52
San Diego 50
Helsinki 48
London 48
Phoenix 48
Montreal 42
Tokyo 37
Ancona 36
Washington 36
Chennai 35
Atlanta 32
Johannesburg 32
Rome 31
Warsaw 31
Denver 30
Elk Grove Village 29
Haiphong 28
Da Nang 27
Brooklyn 26
Amsterdam 25
Pune 25
Columbus 24
Toronto 24
Frankfurt am Main 23
Rio de Janeiro 22
Stockholm 22
Porto Alegre 20
Guangzhou 19
Miano 19
Mexico City 18
Shanghai 18
Manchester 17
Wuhan 17
Brussels 16
Poplar 16
Brasília 14
Hải Dương 14
New Delhi 14
Paris 14
San Francisco 14
Belo Horizonte 13
Boston 13
Campinas 13
Nuremberg 13
Baghdad 12
Baku 12
Cagliari 12
Curitiba 12
Irving 12
Norwalk 12
Salt Lake City 12
Tashkent 12
Thái Nguyên 12
Guayaquil 11
Izmir 11
Miami 11
Naples 11
Salvador 11
San José 11
Biên Hòa 10
Totale 11.801
Salva come PNG Salva come JPEG
Nome #
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 264
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 237
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy 233
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 228
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 214
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 213
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 211
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 207
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 207
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 206
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 205
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 203
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 201
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 201
Optimal management of resected gastric cancer 196
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 194
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 192
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 192
5-Fluorouracil pharmacogenomics: still rocking after all these years? 182
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 181
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 180
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 176
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 176
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 174
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. 171
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 171
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 170
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab 169
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 168
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 167
Benefits and limitations of a multidisciplinary approach in cancer patient management 167
Adjuvant treatment after surgical resection 164
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 163
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 163
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 163
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 159
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 159
BRAF-mutant colorectal cancer, a different breed evolving 158
Panitumumab for the treatment of metastatic colorectal cancer: A review 157
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 155
Trattamento del carcinoma del pancreas. Attualità e prospettive 155
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 155
Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study 154
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 154
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 154
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 152
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 151
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 151
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type 150
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 150
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 149
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 148
Novel perspectives for the treatment of gastric cancer: From a global approach to a personalized strategy 147
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 147
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 147
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 146
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. 145
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 145
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase 145
BRCA mutations and gastrointestinal cancers: When to expect the unexpected? 145
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 144
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 144
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 143
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 143
New Insights into Hormonal Therapies in Uterine Sarcomas 143
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 142
Screening of psychological distress in oncology and hematology department at Ospedali Riuniti Ancona 141
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 140
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 139
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 139
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 137
Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study 136
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 136
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 135
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 134
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 134
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 133
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 133
Selecting the best treatment for an individual patient. 129
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 127
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 127
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 126
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? 126
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 125
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 123
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 122
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 121
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab 121
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 120
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 120
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 119
Gastric cancer: Therapeutic choices in advanced disease 118
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 118
Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. 117
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. 115
Tumor angiogenesis as predictive factor for site of relapse in patients with gastric cancer: biological and clinical implications 115
The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language? 113
Identificazione di markers prognostici in pazienti con carcinoma colo-rettale metastatico trattati con Regorafenib 113
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan 112
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 112
Totale 15.622
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.463
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.463
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022583 0 0 0 0 6 60 34 58 62 112 92 159
2022/20232.081 132 250 137 140 120 512 1 99 436 24 192 38
2023/20241.154 175 25 99 131 164 315 12 41 2 26 19 145
2024/20252.446 315 190 62 41 125 100 241 92 455 212 302 311
2025/20267.308 492 521 416 822 926 531 1.184 652 572 645 217 330
2026/20271.563 285 327 264 638 49 0 0 0 0 0 0 0
Totale 18.831